DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claims 1-8 are pending in the instant application. Claims 1-7 are rejected. Claim 8 is objected.
Information Disclosure Statement
The information disclosure statement filed on July 15, 2026 has been considered and a signed copy of form 1449 is enclosed herewith.
Response to Amendment and Arguments/Remarks
The amendment and arguments/remarks filed on August 26, 2026 have been fully considered and entered into the application. With regards to the 35 U.S.C. 101 and 35 U.S.C. 112(b) rejections, Applicant argues “The above two rejections appear to mischaracterize the claim format. Claim 1 recites ‘A composition for use in preventing or suppressing refeeding syndrome, the composition comprising an mTOR inhibitor.’ This is a composition claim (a product), not a method/process claim. The ‘for use in’ language defines the intended therapeutic application of the composition but does not convert it into a process claim. The cases cited by the Examiner (Ex parte Dunki and Clinical Products V. Brenner) address pure ‘use’ claims that attempt to claim a method without steps; thus, they do not apply to composition claims with functional limitations.” This argument is found to be fully persuasive and the rejections have been withdrawn. With regards to the 35 U.S.C. 112(a) rejection, Applicant argues “To satisfy the written description requirement, a patent specification must describe the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention. See MPEP §2163. In this regard, the specification discloses in paragraph [0011]…claims 1 and 6 have been amended to recite specific mTOR inhibitors.” This argument is found to be partially persuasive (i.e., the amended claims 1 and 6 recite the limitations: “rapalogs,” “ATP-competitive mTOR kinase inhibitors” and “foods containing a ketone body” for which the specification does not provide an adequate written description to convey that the inventors where in possession of the full scope of the claimed invention) and the rejection is maintained, but altered slightly, and described below. With regards to the 35 U.S.C. 102(a)(1) rejection as being anticipated by US 2019/0142819 A1, Applicant argues “Kremer is directed to the treatment of renal cancer with a combination of lenvatinib and everolimus (which is an mTOR inhibitor) and specifically addresses the problem of reducing the occurrence of complications and adverse events. The medical indication of Kremer thus is different from the refeeding syndrome, and the treatment of chronic malnourished patients who potentially could develop the refeeding syndrome is not anticipated, either...Since Kremer does not describe the refeeding of malnourished patients, it cannot anticipate the treatment of the refeeding syndrome…Kremer neither relates to the treatment of the refeeding syndrome, nor is there any indication in Kremer that an mTOR inhibitor may be effective against hypokalemia and hypophosphatemia.” This argument is found to be fully persuasive and the rejection has been withdrawn.
Claim Rejection - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1-6 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
Specifically, claims 1 and 6 recite the limitations: “rapalogs,” “ATP-competitive mTOR kinase inhibitors” and “foods containing a ketone body” for which the specification does not provide an adequate written description to convey that the inventors where in possession of the full scope of the claimed invention.
Regarding the requirement for adequate written description of chemical entities,
Applicant's attention is directed to the MPEP §2163. In particular, Regents of the
University of California v. Eli Lilly & Co., 119 F.3d 1559, 1568 (Fed. Cir. 1997), cert.
denied, 523 U.S. 1089, 118 S. Ct. 1548 (1998), holds that an adequate written
description requires a precise definition, such as by structure, formula, chemical name,
or physical properties, "not a mere wish or plain for obtaining the claimed chemical
invention.” Eli Lilly, 119 F.3d at 1566. The Federal Circuit has adopted the standard set
forth in the Patent and Trademark Office ("PTO") Guidelines for Examination of Patent
Applications under the 35 U.S.C. 112.1 "Written Description" Requirement
("Guidelines"), 66 Fed. Reg. 1099 (Jan. 5, 2001), which state that the written description
requirement can be met by "showing that an invention is complete by disclosure of
sufficiently detailed, relevant identifying characteristics," including, inter aria, "functional
characteristics when coupled with a known or disclosed correlation between function
and structure..." Enzo Biochem, Inc. v. Gen-Probe Inc., 296 F.3d 316, 1324-25 (Fed.
Cir. 2002) (quoting Guidelines, 66 Fed. Reg. at 1106 (emphasis added)). Moreover,
although Eli Lilly and Enzo were decided within the factual context of DNA sequences,
this does not preclude extending the reasoning of those cases to chemical structures in
general. Univ. of Rochester v. G.D. Searle & Co., 249 Supp. 2d 216, 225 (W.D.N.Y.
2003).
Medicinal chemistry and pharmacology are unpredictable areas. Even carefully designed inhibitors do not always function as expected. It is generally unpredictable whether any mTOR inhibitor (i.e., rapalogs of rapamycin, ATP-competitive mTOR kinase inhibitors and foods containing a ketone body) would possess the ability to prevent or suppress refeeding syndrome in a subject. For strong inhibitors of mTOR, for example, some structure-activity-relationship may be ascertained from structurally similar derivatives; however, the degree of structural similar must be high in order to expect similar properties. For new or untested compounds, mTOR inhibition is largely unpredictable.
It is disclosed in the specification (see page 4) that “the mTOR inhibitor can be selected from a wide range of known mTOR inhibitors. Examples of usable mTOR inhibitors include rapamycin (also referred to as ‘sirolimus’) and rapalogs (also referred to as ‘rapamycin derivatives’), ATP-competitive mTOR kinase inhibitors, and foods containing a ketone body. The composition of the present invention preferably contains rapamycin. Examples of rapalogs include deforolimus, everolimus, and temsirolimus. Examples of ATP-competitive mTOR kinase inhibitors include Torin-1, Torin-2, and vistusertib. Examples of foods containing a ketone body include acetoacetic acid, 3- hydroxyacetic acid, salts thereof, and derivatives thereof. The composition of the present invention may contain only one mTOR inhibitor, or two or more mTOR inhibitors.”
However, there is no particular structure required as long as the therapeutic agent is able to inhibit mTOR. In other words, the specification does not ascribe any structure to the inhibiting function. Therefore, Applicant has not described the genus in a manner that would allow one skilled in the art to immediately envisage all the compounds contemplated for use. As such, the claims lack adequate written description for the many compounds embraced by the claimed rapalogs, ATP-competitive mTOR kinase inhibitors, and foods containing a ketone body.
It is also noted that the working examples in the specification (i.e., effect of rapamycin on blood phosphorus concentration after refeeding to protein-undernourished rats and effect of rapamycin on phosphorylated mTOR protein expression in undernourished rats see [0044]-[0056] and pages 11-18) all involve rapamycin as the mTOR inhibitor.
The description requirement of the patent statue requires a description of an
invention, not an indication of a result that one might achieve if one made that invention.
See In re Wilder, 736, F.2d 1516, 1521, 222 USPQ 369, 372-73 (Fed. Cir. 1984)
(affirming rejection because the specification does "little more than outlin[e] goals
appellants hope the claimed invention achieves and the problems the invention will
hopefully ameliorate.") Accordingly, it is deemed that the specification fails to provide
adequate written description for the genus of the claims and does not reasonably
convey to one skilled in the relevant art that the inventor(s), at the time the application
was filed, had possession of the entire scope of the claimed invention.
Although the prior art discloses a number of different classes of inhibitors of mTOR, a person of ordinary skill in the art could not reasonably predict whether an untested compound would be able to function as a mTOR inhibitor because definitive structure-function correlations have not been established in the prior art. It is even more difficult to be able to predict whether an untested generic mTOR inhibitor would be able to be used to prevent or suppress refeeding syndrome. Some exceptions may extend to compounds that share a high degree of structural similarity to known mTOR inhibitors, for example, in the prior art. However, the claim encompasses both known and unknown compounds that are structurally divergent from known mTOR inhibitors. The example in the specification (i.e., rapamycin) and the prior art do not sufficiently represent the vast structural diversity of small molecules and biomolecules embraced by the claims. Due to the high degree of unpredictability generally associated with inhibition and the lack of structure-function correlation, a person of ordinary skill in the art would reasonably conclude that the inventors did not possess all of the mTOR inhibitors claimed (i.e., rapalogs of rapamycin, ATP-competitive mTOR kinase inhibitors, and foods containing a ketone body). Because the specification does not provide sufficient structural information to distinguish the claimed inhibitors from other entities, the claims lack written description. Also, since Applicant provides no description beyond what a person of skill in the art would already know, Applicant has not demonstrated possession of the instantly claimed compositions.
This rejection can be overcome by amending the claims to be limited to the use of the specific mTOR inhibitors: rapamycin, rapalogs selected from the group consisting of deforolimus, everolimus, and temsirolimus; ATP-competitive mTOR kinase inhibitors selected from the group consisting of Torin-1, Torin-2, and vistusertib; and foods containing a ketone body selected from the group consisting of acetoacetic acid, 3-hydroxyacctic acid, and salts thereof.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1-5 and 7 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Tataranni et al. (American Journal of Transplantation 2011; 11: 1656-1664).
Tataranni et al. discloses administering rapamycin to kidney transplant recipients (see abstract). Therefore, a composition comprising rapamycin is administered to the patients and a composition for use in preventing or suppressing refeeding syndrome, the composition comprising an mTOR inhibitor and preventing or suppressing refeeding syndrome wherein the mTOR inhibitor is rapamycin of the instant claims is anticipated by the reference.
With respect to the art rejection above over the claims, it is noted that the reference does not teach that the composition can be used in the manner instantly claimed (i.e., for use in preventing or suppressing refeeding syndrome). However, the intended use of the claimed compositions does not patentably distinguish the compositions, per se, since such disclosed use is inherent in the reference composition. In order to be limiting, the intended use must create a structural difference between the claimed compositions and the prior art composition. In the instant case, the intended use does not create a structural difference, thus the intended use is not limiting.
Claim Objections
Claim 8 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to KRISTIN ANN VAJDA whose telephone number is (571)270-5232. The examiner can normally be reached Mon-Fri 6:00-4:00.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Alstrum-Acevedo can be reached on 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/KRISTIN A VAJDA/Primary Examiner, Art Unit 1622